Medicenna Announces Results of Annual Meeting of Shareholders
09/21/2022 - 05:00 PM
TORONTO and HOUSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the voting results from the Company’s annual meeting of shareholders held today, September 21, 2022 (the "Meeting").
Medicenna is pleased to announce that all of the nominees listed in the management proxy circular dated August 2, 2022 were elected as directors. Each of the directors was elected with greater than 97% of the votes cast by shareholders present at the Meeting or represented by proxy. The results of the vote are detailed below:
Nominee Votes For % of Votes % of Votes Dr. Fahar Merchant 24,859,038 97.878 538,956 2.122 Mr. Albert Beraldo 24,877,225 97.950 520,768 2.050 Ms. Karen Dawes 24,902,175 98.048 495,818 1.952 Dr. John (Jack) Geltosky 24,728,697 97.365 669,296 2.635 Ms. Rosemina Merchant 24,653,185 97.067 744,808 2.933 Dr. Chandrakant Panchal 24,820,996 97.728 576,997 2.272 Dr. John Sampson 24,840,678 97.806 557,315 2.194
Medicenna shareholders also voted to appoint PricewaterhouseCoopers LLP as auditor of the Company.
A total of 57.468% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.
About Medicenna Bi functional S uperK ine I mmunoT herapies ) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.
Further Information
For further information about the Company please contact:
Elizabeth Williams, Chief Financial Officer, 416-648-5555, ewilliams@medicenna.com
Investor Contact
For more investor information, please contact:
Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, daniel@lifesciadvisors.com
Medicenna Therapeutics Corp
MDNA Rankings
#5212 Ranked by Stock Gains
MDNA Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
About MDNA
medicenna is a clinical stage immunotherapy company developing novel highly selective versions of il-2, il-4 and il-13 superkines and first in class empowered cytokines (ecs). our mission is to become the leader in the development and commercialization of targeted ecs and superkines for the treatment of a broad range of cancers and immune-mediated diseases. we seek to achieve these successful treatments by drawing on our expertise, and that of world-class collaborators, to develop a unique set of superkines. these superkines can be developed either on their own as short or long-acting therapeutics or fused with pro-apoptotic proteins in order to precisely deliver potent cell-killing agents to the cancer cells as well as the immunosuppressive tumor micro-environment and the cancer stem cells without harming healthy cells. superkines can also be fused with other types of proteins such as antibodies to generate novel “immunocytokines” or combined with other treatment modalities such as ca
